The complexity of the regulatory approval process for labels increases with each clinical phase, as patient numbers increase, from 10-20 patients in Phase 1 to 100-200 people in Phase II, to as many as 10 000 patients in a Phase III trial. As many Phase III trials are conducted across an increasing number of countries, the complexity of dealing with multiple regulatory agencies is magnified.
Read More